NACDS and University of Pittsburgh partner on pharmacogenomics certificate program
ARLINGTON, Va. – The National Association of Chain Drug Stores, in partnership with the University of Pittsburgh School of Pharmacy, on Thursday announced plans for a national tour this fall to advance the Test2Learn Community-Based Pharmacogenomics Certificate Program.
“NACDS is excited to announce the availability of University of Pittsburgh content through the NACDS educational platform, Learner Community, for the benefit of practicing pharmacists, students and schools and colleges of pharmacy,” stated Steven Anderson, NACDS president and CEO. “Pharmacogenomics is considered a new frontier in patient care, with great promise for patient outcomes and public health, and the ‘train-the-trainer’ focus of the fall 2016 national tour will expand the knowledge of it exponentially.”
“Participants who have learned using this model tell us it makes a meaningful impact in their education," added Philip Empey, assistant professor, Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy. "Our published outcome data shows students are highly-engaged and achieved better learning outcomes.”
NACDS and the University of Pittsburgh School of Pharmacy adapted Test2Learn from an innovative University platform that enables students to learn by using real genetic data in highly-interactive exercises. The certificate program will include online home study and in-person live components, including an optional activity for learners to undergo personal genomic testing.
At each stop on the national tour, pharmacist participants will engage in the in-person aspect of the program, as well as receive the instruction necessary to administer the training to others.
Pharmacogenomics is a subset of the overarching concept of personalized medicine, which refers to ensuring that each patient receives the right medication and the right dose. Pharmacogenomics seeks to achieve that by predicting a response to a drug based on the individual’s genetic makeup.
Test2Learn teaches the principles of pharmacogenomics as well as its practical implications in disease states such as cardiology, oncology, neurology and infectious diseases, among others. It trains pharmacists to decipher genetic tests, translate that information and make appropriate recommendations for the patient, including clinical decision making, interpretation of patient results and counseling and collaboration with prescribers to help optimize patient medication regimens.
The program will be accredited by the Accreditation Council for Pharmacy Education as a Practice-based Continuing Pharmacy Education activity, as defined by ACPE. The online home study module and the one-day live in-person module total approximately 20 credit hours of pharmacogenomics educational content. Program participants have the unique opportunity to use an anonymous genomic data set, or their own personal data, for the in-person educational module.
The first two-day event will occur on Sept. 26 and 27, 2016 at the University of Pittsburgh. Additional fall tour dates and locations will be announced by summer’s end, and more tour stops will be announced in 2017.
Faculty will include representatives of the University of Pittsburgh. Voluntary genetic testing is being supported by the company 23andMe.
The announcement builds on NACDS’ recent extension of a national tour for another training program of promise for public health: a train-the-trainer program for administering point-of-care testing in community pharmacies. Point-of-care testing improves the treatment of flu, strep throat and other acute and chronic conditions.
Little Clinic inks clinical collaboration with University of Toledo Physicians
NASHVILLE, Tenn. – The Little Clinic, a wholly-owned subsidiary of Kroger, and University of Toledo Physicians on Thursday announced that they have joined forces in a clinical collaboration.
“One of the foundational aspects of The Little Clinic mission is centered around increasing access to health care services close to where people live, work, shop or attend school,” stated Colleen Lindholz, president and CEO of The Little Clinic. “Our collaboration goes a long way in making low-acuity health care services more conveniently and readily available for everyone in the community as well as helps to lower cost and improve patient outcomes.”
“Access to health care services is important for increasing the quality of life for our community,” added Kristopher Brickman, chairman, UT Department of Emergency Medicine. “This collaboration with The Little Clinic offers convenient after-hours care for non-emergency health care and provides a link between community health facilities and UT Physicians primary care physicians and specialists who can provide high levels of expertise, the resources to handle the most complex diagnoses and access to the latest and safest medical advances.”
The Little Clinic first opened in the Toledo region in early 2015 and now operates four clinics in the area.
Through this new relationship, UT Physicians will be a referral source for the nurse practitioners and The Little Clinic providers in Toledo.
Theranos dealt severe blow by CMS
PALO ALTO, Calif. — Less than one month following Walgreens decision to terminate its relationship with Theranos, the blood-testing lab on Thursday announced that the Centers for Medicare & Medicaid Services has revoked the company's CLIA certificate, among other sanctions. The revocation of Theranos' CLIA certificate precludes the owners and operators of Theranos from owning, operating or directing a lab until at least July 2018.
“We accept full responsibility for the issues at our laboratory in Newark, Calif., and have already worked to undertake comprehensive remedial actions," stated Elizabeth Holmes, CEO Theranos. "Those actions include shutting down and subsequently rebuilding the Newark lab from the ground up, rebuilding quality systems, adding highly experienced leadership, personnel and experts, and implementing enhanced quality and training procedures,” she said. “While we are disappointed by CMS’ decision, we take these matters very seriously and are committed to fully resolving all outstanding issues with CMS and to demonstrating our dedication to the highest standards of quality and compliance.”
In addition to the revocation of Theranos' CLIA certificate, the full list of CMS sanctions include:
- Limitation of the laboratory’s CLIA certificate for the specialty of hematology;
- A civil money penalty;
- A directed portion of a plan of correction;
- Suspension of the laboratory’s approval to receive Medicare and Medicaid payments for any services performed for the specialty of hematology; and
- Cancellation of the laboratory’s approval to receive Medicare and Medicaid payments for all laboratory services.
While the revocation would not take effect for 60 days, the company will not conduct any patient testing in the Newark lab until further notice, Theranos announced. During this period, the company will continue to work with CMS to resolve and remediate outstanding issues in the Newark lab, and will continue to provide services to its customers through its Arizona lab, Theranos stated.
Walgreens last month ended its relationship with Theranos. “In light of the voiding of a number of test results, and as the Centers for Medicare and Medicaid Services has rejected Theranos’ plan of correction and considers sanctions, we have carefully considered our relationship with Theranos and believe it is in our customers’ best interests to terminate our partnership,” stated Brad Fluegel, Walgreens SVP and chief health care commercial market development officer, at the time of the decision.